A compound that selectively binds to cd123 and use thereof to kill hematologic cancer progenitor cells
CA 2895884 C · Owner: University Of Kentucky Research Foundation · Inventors: Jordan, Craig T.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Primitive or progenitor hematologic cancer cells have been implicated in the early stages and development of leukemia and malignant lymphoproliferative disorders including acute myelogenous leukemia (AML) chronic myelogenous leukemia (CML) and chronic lymphoid leukemia (CLL). Interleukin-3 receptor alpha chain (IL-3R.alpha. or CD123) is strongly expressed on progenitor hematologic cancer cells but is virtually undetectable on normal bone marrow cells. The present invention provides methods of impairing progenitor hematologic cancer (e.g. leukemia and lymphomic) cells by selectively targeting cells expressing CD123. These methods are useful in the detection and treatment of leukemias and …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed March 6, 2001 and granted April 23, 2019. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended March 6, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by March 6, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.